violate Section 7 of the Clayton Act and Section 5 of the Federal Trade Commission Act. I find reason to believe that the joint venture, if consummated, would affect competition adversely in the refining of asphalt in Northern California and, therefore, support Paragraph VII of the order, which provides relief in that market. I do not find reason to believe the other violations of law alleged in the complaint and, therefore, dissent from Paragraphs II, III, IV and V of the order, which require divestitures in other markets. Although the allegation relating to refineries in the northwestern United States is arguably valid, on balance, I cannot support it and, therefore, cannot support Paragraph II of the order. The complaint allegations that support Paragraphs III, IV and V of the order seem to me far removed from our usual analysis under the merger guidelines.

I understand that the parties have negotiated identical relief with various state attorneys general and that the divestitures in the proposed Commission order will be required in any event. My obligation, however, is to apply federal law as I see it.

[FR Doc. 97–33872 Filed 12–29–97; 8:45 am]

BILLING CODE 6750–01–M

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of January meeting.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. No. 92–463), as amended, notice is hereby given that the Federal Accounting Standards Advisory Board will hold a two day meeting on Thursday and Friday, January 22 and 23, 1998, from 9:00 A.M. to 4:00 P.M. in Room 7C13 of the General Accounting Office building, 441 G St., N.W., Washington, D.C.

The purpose of the meeting is to discuss the following issues: (1) Accounting for Loans and Loan Guarantees; (2) Accounting for Property and Plant Equipment; (3) Accounting for Social Insurance; and (4) the addition of new projects for 1998.

Any interested person may attend the meeting as an observer. Board discussions and reviews are open to the public.

FOR FURTHER INFORMATION CONTACT: Wendy Comes, Executive Director, 441 G St., N.W., Room 3B18, Washington, D.C. 20548, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. No. 92–463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: December 23, 1997.

Wendy M. Comes,

Executive Director.

[FR Doc. 97–33938 Filed 12–29–97; 8:45 am]

BILLING CODE 1610–01–M

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090–0040]

Proposed Collection; Comment Request Entitled Application for Shipping Instructions and Notice of Availability

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of request for public comments regarding reinstatement to a previously approved OMB clearance (3090–0040).

SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the Office of Acquisition Policy has submitted to the Office of Management and Budget (OMB) a request to review and approve a reinstatement of a previously approved information collection requirement concerning Application for Shipping Instructions and Notice of Availability.

DATES: Comment Due Date: March 2, 1998.

ADDRESSES: Comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, should be submitted to: Edward Springer, GSA Desk Officer, Room 3235, NEOB, Washington, DC 20503, and to Marjorie Ashby, General Services Administration (MVP), 1800 F Street NW, Washington, DC 20405.

FOR FURTHER INFORMATION CONTACT: Marcia Crockett, Acquisition Operations & Electronic Commerce Center, Supply Management Division, (703) 305–7551.

SUPPLEMENTARY INFORMATION:

A. Purpose

The GSA is requesting the Office of Management and Budget (OMB) to reinstate information collection, 3090–0400, concerning Application for Shipping Instructions and Notice of Availability. This information collection supports and justifies the markup of the six percent surcharge for the GSA export reimbursable program. It also is used to evaluate and obtain the best cube utilization of shipping vans and containers for export direct delivery shipments. The form contains data necessary to prepare Transportation Control and Movement Documents (TCMD) which are required when material enters the Defense Transportation System.

B. Annual Reporting Burden

Respondents: 500; *annual responses*: 4,000; *average hours per response*: .20; *burden hours*: 1,333.

COPY OF PROPOSAL: A copy of this proposal may be obtained from the GSA Acquisition Policy Division (MVP), Room 4011, GSA Building, 1800 F Street NW, Washington, DC 20405, or by telephoning (202) 501–3822, or by faxing your request to (202) 501–3341.

Dated: December 19, 1997.

Ida M. Ustad,

Deputy Associate Administrator, Office of Acquisition Policy.

[FR Doc. 97–33905 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–61–M

GENERAL SERVICES ADMINISTRATION

Federal Supply Service; Broker and Direct Move Management Services Provider Participation in the General Services Administration's Centralized Household Goods Traffic Management Program (CHAMP)

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of proposed program changes for comment: Extension of comment period.

SUMMARY: This document extends the comment period of the document published at 62 FR 64225, December 4, 1997, to January 12, 1998. Earlier this year, GSA provided the household goods transportation industry an opportunity to comment on its draft 1997 Household Goods Tender of Service (HTOS). GSA has received and reviewed the industry's comments on the draft 1997 HTOS and is in the process of making appropriate revisions to the document before issuing it in final. The provisions contained in this notice apply to household goods transportation broker and direct move management services provider participants in CHAMP and were not included in the original draft HTOS. We are offering these provisions for industry review and comment at this time.

DATES: Please submit your comments by January 12, 1998.

ADDRESSES: Mail comments to the Travel and Transportation Management

Staff (FBX), General Services Administration, Washington, DC 20406. Attn: **Federal Register** Notice. GSA will consider your comments in developing the final move management services provisions. In the interim, rates filed in response to GSA's 1996 Request for Offers have been extended for 90 days from October 31, 1997 to January 29, 1998.

FOR FURTHER INFORMATION CONTACT: Larry Tucker, Senior Program Analyst, Travel and Transportation Management Staff, FSS/GSA, 703–305–7660.

SUPPLEMENTARY INFORMATION: The proposed changes appear at 62 FR 64225, December 4, 1997.

Dated: December 22, 1997.

Janice Sandwen,

Director, Travel and Transportation Management Staff.

[FR Doc. 97–33862 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–24–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Three Meetings of the National Bioethics Advisory Commission (NBAC) and its Subcommittees

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of three meetings of the National Bioethics Advisory Commission and its subcommittees. The Commission will continue addressing the protection of the rights and welfare of human subjects in research including decisionally impaired populations and the federal agency survey as well as issues in genetics including genetics information and tissue storage. The meetings are open to the public and opportunities for statements by the public will be provided.

Dates, Times, and Locations

Genetics Subcommittee: January 6, 1998, 1:30 pm–5:00 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

Full Commission: January 7, 1998, 8:00 am–5:00 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

Human Subjects Subcommittee: January 8, 1998, 8:00 am—12:30 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975 on October 3, 1995. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council and other entities on bioethical issues arising from the research on human biology and behavior, and in the applications of that research including clinical applications.

Public Participation

The meetings are open to the public with attendance limited by the availability of space. Members of the public who wish to present oral statements should contact Ms. Patricia Norris by telephone, fax machine, or mail as shown below prior to the meeting as soon as possible. The Chairs of the full Commission and subcommittees will reserve time for presentations by persons requesting to speak. The order of speakers will be assigned on a first come, first serve basis. Individuals unable to make oral presentations are encouraged to mail or fax their comments to the NBAC staff office at least four business days prior to the meeting for distribution to the subcommittee members or Commission and inclusion in the public record. Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Patricia Norris, National Bioethics Advisory Commission, MSC–7508, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892–7508, telephone 301–402–4242, fax number 301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, National Bioethics Advisory Commission.

[FR Doc. 97–33792 Filed 12–29–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Orphan Products Board; Notice of Public Meeting

AGENCY: Office of Public Health and Science.

ACTION: Notice of meeting.

SUMMARY: The Department of Health and Human Services and the Office of Public Health and Science (Office of the Assistant Secretary for Health) are announcing a public meeting of the Orphan Products Board. The purpose of this meeting is to facilitate the research, development, and approval of orphan products and to coordinate Government activities with the private sector to achieve these goals. In this meeting there will be an opportunity for interested persons to present information and views on the issue of orphan products development.

DATES: The public meeting be held on Thursday, February 12, 1998, from 2 p.m. to 5 p.m. Requests to attend or participate should be sent by February 4, 1998.

ADDRESSES: The public meeting will be held at the Hubert H. Humphrey Bldg., 200 Independence Ave. S.W., Washington, DC. Written requests to attend or participate should be sent to Robert F. Steeves, Orphan Products Board, Food and Drug Administration (HF–35), 5600 Fishers Lane, rm. 8–73, Rockville, MD 20857, FAX 301–443–4915. Requests from nongovernmental persons should include full name, address, affiliation, and social security number for use in obtaining security clearance for entry into the facility.

FOR FURTHER INFORMATION CONTACT: Robert F. Steeves, Orphan Products Board, Food and Drug Administration (HF–35), 5600 Fishers Lane, Rockville, MD 20857, 301–827–3666.

SUPPLEMENTARY INFORMATION: An orphan drug is a drug for the treatment of a rare disease or condition which either has: (1) A prevalence in the United States of under 200,000 persons; or (2) a higher prevalence and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. The Orphan Drug Act (Pub. L. 97–414) enacted on January 4, 1983, as amended, established a number of incentives to encourage the development and marketing of orphan drugs.

The Orphan Drug Act also established an Orphan Products Board to promote the development of drugs and devices for rare diseases or conditions and to assure appropriate coordination among interested Federal agencies, manufacturers, and organizations representing patients with rare diseases.

The Orphan Products Board is chaired by the Assistant Secretary for Health. The Board is composed of representatives from the Department of Health and Human Services (DHHS), the Department of Veterans Affairs (DVA), The National Institute of Disability and Rehabilitation Research (NIDRR), the Social Security Administration (SSA), and the Department of Defense (DOD). Within DHHS, representatives from the